Quick Dispatch:
Your tirzepatide children Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide children Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about tirzepatide children Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide children Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial in your area.
Big update in pediatric diabetes care 🩺 Mounjaro® (tirzepatide) is now FDA-approved for children ≥10 years old with Type 2 diabetes as an adjunct to diet and exercise. What this means ⬇️
27.49
Lilly's Mounjaro helps improve blood sugar control in children in late-stage trial
29.89
01774-X/asset/29980040-bf4f-4117-ad08-f431cfca3ffc/main.assets/gr3_lrg.jpg)
Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial
22.08
Tirzepatide reduces HbA1c, BMI for children and adolescents with type 2 diabetes
25.50
Medscape - The SURPASS-PEDS trial shows tirzepatide delivers durable glycemic control and weight benefit in youth with type 2 diabetes, the first therapy to show this effect. http://ms.spr.ly/6180sWS1i
24.39
EASD25: Lilly's Mounjaro delivers notable glycaemic control in Phase III paediatric trial
20.60
🚨 Diabetes News Update for Families 🚨 Big update in pediatric diabetes care 👇 Mounjaro (tirzepatide) is now approved for children and adolescents ages 10 and older with type 2 diabetes. This
29.80
